NDRA

Over the past six months, ENDRA Life Sciences, Inc. stock price has been impacted by several events. On November 17, 2025, the company recapped major milestones and announced its Third Quarter 2025 financial results, which coincided with a -7.46% stock movement. On November 20, 2025, positive results from a feasibility study demonstrating TAEUS Liver's ability to accurately quantify liver fat fraction were announced, followed by a -15.19% stock movement. On December 4, 2025, additional feasibility results showed strong concordance between TAEUS Liver and MRI-PDFF, associated with a -7.67% stock movement. On February 26, 2026, favorable results from a new study demonstrated the TAEUS device's robust intra-user repeatability and inter-user reproducibility, leading to a +2.89% stock movement. On March 25, 2026, ENDRA Life Sciences initiated a review of strategic alternatives, which saw an +8.38% increase in stock price. On March 31, 2026, the company reported its Fourth Quarter and Full Year 2025 financial results and flagged "going-concern risk" and announced a pivot to a digital asset treasury, also reporting sharply cutting 2025 operating costs. On April 21, 2026, an 8-K filing indicated that an equity shortfall put ENDRA Life Sciences at renewed Nasdaq delisting risk. As of May 1, 2026, the share price was $4.97, representing a decline of 20.48% over the past year.